1-Bromo-3-(difluoromethoxy)benzene | CAS:262587-05-3

We serve 1-Bromo-3-(difluoromethoxy)benzene CAS:262587-05-3 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
1-Bromo-3-(difluoromethoxy)benzene

Chemical Name:1-Bromo-3-(difluoromethoxy)benzene
CAS.NO:262587-05-3
Synonyms:1-Bromo-3-(difluoromethoxy)benzene
3-Bromophenyl difluoromethyl ether
3-(Difluoromethoxy)bromobenzene
 
Physical and Chemical Properties:
Density 1.6±0.1 g/cm3
Boiling Point 197.2±30.0 °C at 760 mmHg
Molecular Formula C7H5BrF2O
Molecular Weight 223.015
Flash Point 87.0±8.8 °C
Vapour Pressure 0.5±0.4 mmHg at 25°C
Index of Refraction 1.492
 
Specification:
Appearance:Colorless transparent liquid
Assay:≥98.0%
 
Packing:200 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Organic synthesis.



Contact us for information like 1-Bromo-3-(difluoromethoxy)benzene chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-(Difluoromethoxy)bromobenzene physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-Bromophenyl difluoromethyl ether Use and application,3-Bromophenyl difluoromethyl ether technical grade,usp/ep/jp grade.


Related News: The move could force international drugmakers to further cut prices and enable copycat medicines to replace imported off-patent brands at faster pace.Siloxanes and Silicones, Me 3,3,3-trifluoropropyl, Me vinyl, hydroxy-terminated manufacturer At present, there are more than 8,000 domestic API manufacturers, but they mainly produce bulk APIs with low technical content.4-[(6-oxo-1H-pyrimidin-2-yl)amino]benzonitrile supplier The Transport Security Administration (TSA) will issue a new security directive to airlines from Sunday, according to a person briefed on the restrictions.2-Bromo-4-butanolide vendor ll coronaviruses are zoonotic, meaning they are transmitted between animals and people.As a result, the Company’s platform is uniquely capable of overcoming numerous limitations associated with the production of cell therapies using patient- or donor-sourced cells, which is logistically complex and expensive and is subject to batch-to-batch and cell-to-cell variability that can affect clinical safety and efficacy.